Abstract: The present disclosure describes a dosing regimen of an IL-10F129S expression construct for treating an inflammatory joint disease (e.g., osteoarthritis) in a subject. Methods are provided for treating an inflammatory joint disease in a subject by injecting a first dose and second dose of a composition comprising an IL-10F129S expression construct into an inflamed joint of the subject according to a dosing regimen wherein the two doses of the expression construct are administered to a subject approximately 150-360 days apart. The present disclosure also provides kits comprising a first and second dose of an IL-10F129S expression construct. The kits may be useful for treating an inflammatory joint disease in a subject.

Abstract: An IOL system includes a capsular ring having a concave exterior surface extending around its circumference that is configured, upon insertion into a capsular bag of a patient's eye, to engage an equatorial region of the capsular bag. The concave exterior surface extends between an anterior surface and a posterior surface of the capsular ring. A first one or more flaps are arranged on the anterior surface such that at least a portion of each of the first one or more flaps, upon insertion into the capsular bag of a patient's eye, engages an anterior portion of the capsular bag. Similarly, a second one or more flaps are arranged on the posterior surface such that at least a portion of each of the second one or more flaps, upon insertion into a capsular bag of a patient's eye, engages a posterior portion of the capsular bag.

Abstract: The present invention encompasses improved morphian compositions and methods of use of the improved compositions for modulating neuropathic pain, opioid-induced glial activation, or a combination thereof beyond what is currently known in the art. The methods involve administering the compound of Formula I to a subject.

Abstract: The present invention encompasses improved morphian compositions and methods of use of the improved compositions for modulating neuropathic pain, opioid-induced glial activation, or a combination thereof beyond what is currently known in the art. The methods involve administering the compound of Formula I to a subject.

Abstract: A non-woven fabric comprising bicomponent fibers. The non-woven fabric has a core containing polylactic acid (PLA-1), coated with an envelope containing polylactic acid (PLA-2). The fibers are characterised in that PLA-1 is a copolymer of lactic acid monomers L1 and lactic acid monomers D1, and PLA-2 is a copolymer of lactic acid monomers L2 and lactic acid D2, whose D2 monomers rate is greater than the monomers rate D1 of PLA-1. The core further contains a polymeric plasticizer. The non-woven fabric may be used for making coffee filters and/or capsules via a thermoforming process for use in a percolating apparatus.

Abstract: The present invention encompasses improved morphian compositions and methods of use of the improved compositions for modulating neuropathic pain, opioid-induced glial activation, or a combination thereof beyond what is currently known in the art. The methods involve administering the compound of Formula I to a subject.

Abstract: An IOL system includes a capsular ring having a concave exterior surface extending around its circumference that is configured, upon insertion into a capsular bag of a patient's eye, to engage an equatorial region of the capsular bag. The concave exterior surface extends between an anterior surface and a posterior surface of the capsular ring. A first one or more flaps are arranged on the anterior surface such that at least a portion of each of the first one or more flaps, upon insertion into the capsular bag of a patient's eye, engages an anterior portion of the capsular bag. Similarly, a second one or more flaps are arranged on the posterior surface such that at least a portion of each of the second one or more flaps, upon insertion into a capsular bag of a patient's eye, engages a posterior portion of the capsular bag.

Abstract: A receiver assembly (100) and data communications method are disclosed. In one arrangement, a receiver assembly (100) comprises a concentration stage (14). The concentration stage (14) receives radiation via an input surface (120) and outputs concentrated radiation via an output surface (122). The concentration stage comprises a wavelength converting member (6) that converts radiation to longer wavelength radiation. An optical element (102) is provided which is such that if a plane wave of radiation is incident on the optical element a spatial distribution of radiation derived from the plane wave on the input surface of the concentration stage varies as a function of a direction of incidence of the plane wave relative to the optical element. A plurality of detectors (42) are provided, each detecting radiation output from a different portion of the output surface of the concentration stage.

Abstract: A receiver assembly (1) has a radiation guide (4) having an elongate form. The length is at least five times longer than all dimensions of the radiation guide perpendicular to the longitudinal axis (3). The guide receives radiation via an outer lateral surface (8), converts the radiation to longer wavelength radiation, and guides the converted radiation to a longitudinal end surface (2). A receiver unit (5) receives radiation output from the longitudinal end surface.

Abstract: The present invention relates to a golf putting practice device for improving golf putting skills

Abstract: The present invention relates to a method of treating a glazing panel from an inside location. Moreover, the present invention relates to a method of treating glazing panels used in windows and patio doors. Initially, a hole is formed on both inside and outside panes on windows and on the side and outside frames of patio doors. Next, a filter is attached to the outside pane to cover the hole whereby the filter membrane is designed to allow the passage of air and inhibit the ingress of moisture. Finally, a seal is used to cover the hole on the inside pane or to ensure that the building air does not enter the interior of the glazing panel. Where the panes are tempered glass, the hole(s) may be drilled through the frame. If necessary, one or more tubes may be inserted through the hole. Various kinds of filters are disclosed.

Abstract: The present invention provides a method of treating pancreatitis comprising administering to a human in need thereof an effective amount of hemin. The administration of hemin is preferably parenteral. In another aspect, the present invention provides a method of pancreatitis prophylaxis comprising administering to a human in need thereof an effective amount of hemin. In a still further aspect, the present invention contemplates a method of inducing an HO gene comprising administering to a human in need thereof an HO-inducing effective amount of hemin. Preferably, the HO gene is the HO-1 gene. In a still further aspect, the present invention contemplates a method of inducing an HO gene in leukocytes for recruitment to the pancreas to treat pancreatitis comprising administering to a human in need thereof an HO-inducing effective amount of hemin.

Abstract: An exemplary embodiment of the present invention has been described above. Those skilled in the art will understand, however, that changes and modifications may be made to this embodiment without departing from the true scope and spirit of the present invention, which is defined by the claims.

Abstract: An exemplary embodiment of the present invention has been described above. Those skilled in the art will understand, however, that changes and modifications may be made to this embodiment without departing from the true scope and spirit of the present invention, which is defined by the claims.

Abstract: The present invention provides a method of treating pancreatitis comprising administering to a human in need thereof an effective amount of hemin. The administration of hemin is preferably parenteral. In another aspect, the present invention provides a method of pancreatitis prophylaxis comprising administering to a human in need thereof an effective amount of hemin. In a still further aspect, the present invention contemplates a method of inducing an HO gene comprising administering to a human in need thereof an HO-inducing effective amount of hemin. Preferably, the HO gene is the HO-1 gene. In a still further aspect, the present invention contemplates a method of inducing an HO gene in leukocytes for recruitment to the pancreas to treat pancreatitis comprising administering to a human in need thereof an HO-inducing effective amount of hemin.

Abstract: The present invention is directed to a carbamazepine-cyclodextrin inclusion complex useful for the parenteral administration of carbamazepine. The carbamazepine-cyclodextrin inclusion complex is prepared by the admixture of a modified cyclodextrin and carbamazepine in a physiologically acceptable fluid. Modified cyclodextrins include 2-hydroxypropyl-beta-cyclodextrin and sulfoalkyl cyclodextrins. More particularly, the sulfoalkyl cyclodextrins are those described and disclosed in U.S. Pat. Nos. 5,134,127 and 5,376,645. A physiologically acceptable fluid includes sterile isotonic water, Ringer's lactate, D5W (5% dextrose in water), physiological saline, and similar fluids suitable for parenteral administration.